AstraZeneca acquires DSM Biologics manufacturing facility in Canada
Royal DSM N.V. announces that AstraZeneca has acquired the biologics manufacturing facility in Montreal, Canada, from DSM Biologics Inc. This transaction will lead to a small book profit for DSM. The facility, occupying 66,000 sq. ft, will be used to manufacture antibody drug candidates for clinical trials and will serve the whole of the AstraZeneca group. Work will now start to re-commission the facility, and AstraZeneca plans to commence full scale production in 2009.
As announced in December 2005, DSM mothballed the Montreal facility as part of its strategy for DSM Biologics. Core to this strategy is the development and out-licensing of a new manufacturing technology platform based on the PER.C6® human cell line, in a joint venture with the Dutch biotechnology company Crucell N.V. DSM and its partner Crucell have recently announced a breakthrough in production yields, achieving 10g/L in the fermentation of monoclonal antibodies, using the PER.C6® technology platform, and stating a target of 20g/L for their near term development efforts.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents

Real-time observation of enzymatic processes on DNA - Insights into the molecular processes involved in the detection of DNA strand breaks

The Mozart effect myth: Listening to music does not help against epilepsy - In the past, Mozart’s music has been associated with numerous ostensibly positive effects on humans, animals, and even microorganisms
Test developed to detect early-stage diseases with naked eye - Prototype ultra sensitive disease sensor developed
Medicyte and PRIMACYT Receive Grant to Develop Human Liver Cells for Cell-based Therapies
Takeda and Galaxy Biotech Sign License Agreement for Galaxy's Investigational Antibodies for the Treatment of Cancer

High-resolution microscope built from LEGO and bits of phone - Research shows constructing microscope improves children’s understanding - enlightening, educational and fun

Green adhesives made from whey - New process for obtaining valuable ethyl acetate
The American Physiological Society - Bethesda, USA

ImevaX GmbH - München, Germany
